Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study.

hydroxyurea - Generic mfg.

bonretinib (OB756) - Biosun Pharma

http://www.ncbi.nlm.nih.gov/pubmed/41060136

Feng Zhang; Guocai Wu; Hu Zhou; Jian Huang; Jie Jin; Lidong Zhao; Lihong Shou; Lili Chen; Pengxiang Guo; Qinchi Liu; Rumeng Li; Tiejun Gong; Yi Zhang; Yile Zhou; Zongjiu Jiao

Oct 8, 2025